Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
HDAC inhibitor
DRUG CLASS:
HDAC inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
chidamide (23)
vorinostat (19)
panobinostat (15)
romidepsin (9)
entinostat (9)
CUDC-907 (8)
OKI-179 (4)
SB939 (4)
belinostat (2)
CG-781 (2)
MGCD0103 (2)
REC-2282 (1)
4SC-202 (1)
JNJ 26481585 (1)
CUDC-101 (0)
givinostat (0)
resminostat (0)
RG2833 (0)
sulforafan alfadex (0)
CKD-581 (0)
CG-745 (0)
kt-3000 series (0)
kt-3283 (0)
VRx-3996 (0)
MTX110 (0)
SHP-141 (0)
OBP-801 (0)
EDO-S101 (0)
VTR-297 (0)
CXD101 (0)
chidamide (23)
vorinostat (19)
panobinostat (15)
romidepsin (9)
entinostat (9)
CUDC-907 (8)
OKI-179 (4)
SB939 (4)
belinostat (2)
CG-781 (2)
MGCD0103 (2)
REC-2282 (1)
4SC-202 (1)
JNJ 26481585 (1)
CUDC-101 (0)
givinostat (0)
resminostat (0)
RG2833 (0)
sulforafan alfadex (0)
CKD-581 (0)
CG-745 (0)
kt-3000 series (0)
kt-3283 (0)
VRx-3996 (0)
MTX110 (0)
SHP-141 (0)
OBP-801 (0)
EDO-S101 (0)
VTR-297 (0)
CXD101 (0)
›
Associations
(106)
News
Trials
Search handles
@DrEzraCohen
@ErikaHamilton9
@RahulBanerjeeMD
@naborala
@stolaney1
@weldeiry
Search handles
@DrEzraCohen
@ErikaHamilton9
@RahulBanerjeeMD
@naborala
@stolaney1
@weldeiry
Filter by
Latest
10ms
Time for limitations on bridging therapy in #MMsm trials to go the way of panobinostat 😉 But yes, I bet it's related to the restriction that bridging be Tx that the patient has already received... even if that means they will be less likely to maintain disease control. (@RahulBanerjeeMD)
10 months ago
Clinical
|
Farydak (panobinostat)
11ms
Romidepsin’s turbulent story is a reminder of the need for regulatory reform of @FDAOncology’s approach to accelerated approval confirmatory trials @NehaMehtaShahMD #17ICML #lymsm (@Eddie_Cliff)
11 months ago
Istodax (romidepsin)
over1year
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflamma… https://t.co/enylYMscmn (@weldeiry)
over 1 year ago
TGM2 (Transglutaminase 2)
over1year
Loss of HLA-I gene expression in prostate cancer is associated with repressive chromatin states, which can be reversed by pharmacological DNMT/HDAC inhibition and increased activation of co-cultured tumor-specific CD8+ T-cells. @JoshLangMD, @UWCarbone https://t.co/GSpMupUUC0 (@CommsBio)
over 1 year ago
CD8 (cluster of differentiation 8)
2years
#ICYMI: Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ #breasttumor microenvironment by @DNSidiropoulos @christine_rafie @FertigLab @RoussosTorres et al. https://t.co/UVzeULt113 @AaronGBaugh @efaithd @VeredStearns @RoisinMConnolly @ltkagohara (@CIR_AACR)
2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
Jingzhuda (entinostat)
2years
Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment by @DNSidiropoulos, @christine_rafie, @FertigLab, @RoussosTorres et al. https://t.co/hftCCeeZVq @AaronGBaugh @efaithd @VeredStearns @RoisinMConnolly @ltkagohara (@CIR_AACR)
2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
Jingzhuda (entinostat)
over2years
Exemstane +/- entinostat: improved PFS 6.3 vs 3.7 mo; ~40% g3 neutropenia; only 6% prior cdk 4/6i Confusing in light of other negative HDACi data (E2112), and in a population that isn't a typical modern era group of pts @OncoAlert #bcsm #SABCS21 (@stolaney1)
over 2 years ago
Clinical
|
CDK4 (Cyclin-dependent kinase 4)
|
Jingzhuda (entinostat)
over2years
Dr. Xu presents exemstane +/- etinostat (HDACi) for #HR+ w/ prior ET: ‼️note: very few w/ CDK4/6 🌟 PFS improved w/ etinostat 3.7 vs. 6.3 months (HR 0.70) 🚫OS no different 🔹ORR and CBR numerically improved #SABCS21 @OncoAlert #bcsm (@ErikaHamilton9)
over 2 years ago
CDK4 (Cyclin-dependent kinase 4) • STAT3 (Signal Transducer And Activator Of Transcription 3)
over2years
Combining HDAC inhibition with anti-PD1 antibody appears active in BAP1 wild-type uveal melanoma. Encouraging since anti-PD1 alone in this disease is not. https://t.co/ickeJPatQr (@DrEzraCohen)
over 2 years ago
BAP1 (BRCA1 Associated Protein 1)
almost3years
Proposed model of how Rnf43 mutations alter the #PancreaticCancer TME to a relatively favorable milieu via HDAC mediated suppression of chemokine ligand CXCL5. Can this be exploited in the clinic? Second manuscript in works with more insights on unexpected Rnf43 role in cancer. (@Aiims1742)
almost 3 years ago
RNF43 (Ring Finger Protein 43) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
|
RNF43 mutation
3years
HDAC Inhibitors in #BreastCancer? Oral taxanes? Dr. Sara Tolaney (@stolaney1), from @DanaFarber, discusses metastatic HER2 negative breast cancer with emerging novel treatment strategies, highlighting some of the exciting data from #SABCS20 https://t.co/AW4sBi7UbC (@TotalHealthConf)
3 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
over3years
FAKi Defactinib /HDAC Vorinostat could potentially change #Glioblastoma #BrainTumor #cancer treatment. 🔺1st thread post🔺 Also, interesting #KRAS G12V slides @udai_banerji @CR_UK @royalmarsdenNHS (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
Zolinza (vorinostat) • defactinib (VS-6063)
over3years
E2112: disapp, despite successful OS improvement of Encore301(phase II), phase III study entinostat+AI (post fulvestrant, some CDK4/6inh in 35%) was negative in both primary endpoint PFS and OS. Beautiful work tho!! pres by Dr. Roisin Connolly #bcsm #SABCS20 (@naborala)
over 3 years ago
P2 data • P3 data
|
CDK4 (Cyclin-dependent kinase 4)
|
Jingzhuda (entinostat)
over5years
VIDEO: Emerging #melanoma therapeutics: #IDO1, #LAG3 & #HDAC inhibitors, with @PAscierto: https://t.co/RL9XXPdkUq @ASCO #ASCO18 #melsm #skcsm #SkinCancer #ImmunoOnc #CheckpointInhibitors #ImmunoOnc #Immunotherapy #ClinicalTrials #CTSM (@VJOncology)
over 5 years ago
Clinical • Checkpoint inhibition • Video
|
IDO1 (Indoleamine 2,3-dioxygenase 1)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login